Clinical trials
Terminated Phase 2 trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
150 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 8 |
| 2007 | 4 |
| 2008 | 11 |
| 2009 | 7 |
| 2010 | 8 |
| 2011 | 5 |
| 2012 | 6 |
| 2013 | 9 |
| 2014 | 7 |
| 2015 | 5 |
| 2016 | 10 |
| 2017 | 14 |
| 2018 | 11 |
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 8 |
| 2022 | 10 |
| 2023 | 1 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 150 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 15 |
| Bayer | 14 |
| Biogen | 5 |
| Bristol-Myers Squibb | 5 |
| Hoffmann-La Roche | 5 |
| Amgen | 4 |
| Boehringer Ingelheim | 4 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Gilead Sciences | 4 |
| Medical University of Vienna | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 13 |
| Colorectal Neoplasms | 7 |
| Crohn Disease | 7 |
| Neoplasm Metastasis | 6 |
| Hypertension, Pulmonary | 5 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Hypertension, Portal | 4 |
| Carcinoma, Renal Cell | 3 |
| Colitis, Ulcerative | 3 |
| Dermatitis, Atopic | 3 |
Trials
Showing 1 to 25 of 150. Each trial links to its page on Pharma Observatory.
50 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.